Addition of tucatinib to trastuzumab and chemotherapy improves survival for patients with metastatic, HER2-positive breast cancer. Printz C. Cancer 2020;126:2113.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Printz C. Addition of tucatinib to trastuzumab and chemotherapy improves survival for patients with metastatic, HER2-positive breast cancer. Cancer 2020;126:2113.
PMID: 32343407